Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children

Trial Profile

Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Antiretrovirals; Hib vaccine conjugate
  • Indications Haemophilus infections; HIV-1 infections; Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms CIPRA Project-4; CIPRA-SA Project-4; CIPRA-SA-4; CIPRA-ZA Project-4; CIPRA-ZA-4
  • Most Recent Events

    • 23 Dec 2010 Planned end date changed from 1 May 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Interim results reported at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention.
    • 19 Aug 2008 Planned end date added (May 2010) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top